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Abstract 
Serratia marcescens is a Gram‑negative bacterium with proven resistance to multiple antibiotics and causative of 
catheter‑associated infections. Bacterial colonization of catheters mainly involves the formation of biofilm. The objec‑
tives of this study were to explore the susceptibility of S. marcescens biofilms to high doses of common antibiotics and 
non‑antimicrobial agents. Biofilms formed by a clinical isolate of S. marcescens were treated with ceftriaxone, kanamy‑
cin, gentamicin, and chloramphenicol at doses corresponding to 10, 100 and 1000 times their planktonic minimum 
inhibitory concentration. In addition, biofilms were also treated with chemical compounds such as polysorbate‑80 
and ursolic acid. S. marcescens demonstrated susceptibility to ceftriaxone, kanamycin, gentamicin, and chlorampheni‑
col in its planktonic form, however, only chloramphenicol reduced both biofilm biomass and biofilm viability. Poly‑
sorbate‑80 and ursolic acid had minimal to no effect on either planktonic and biofilm grown S. marcescens. Our results 
suggest that supratherapeutic doses of chloramphenicol can be used effectively against established S. marcescens 
biofilms.
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Background
Serratia marcescens is a Gram-negative bacterium that 
causes infections in plants, insects, and animals, includ-
ing humans [1]. Initially believed to be non-pathogenic, 
S. marcescens is currently known to cause ocular, pul-
monary, urinary tract, and blood-stream infections [1, 
2]. Recent reports implicate this pathogen in 2.5–7.7% 
of catheter-associated infections such as central line-
associated bloodstream infections (CLABSI) and cath-
eter-associated urinary tract infections [3–5]. In the 
United States alone, an estimated 80,000 catheter-asso-
ciated bloodstream infections occur every year with 
costs up to $56,000 per episode [6]. Bacterial coloniza-
tion of catheters confers a survival advantage and leads 
to the formation of cooperative bacterial communities 
known as “biofilms” [7]. Bacterial biofilms are complex 
surface-adhered communities of viable and dead bac-
teria, encased within an extracellular matrix composed 
of polysaccharide, protein and extracellular DNA [8]. In 
addition, bacteria adhere to host’s epithelial cells through 
formation of biofilm [9, 10]. The ability of S. marcescens 
to form biofilms contributes to its pathogenicity [1, 11]. 
Bacteria in biofilms also exhibit increased resistance to 
antimicrobial agents for reasons such as resistance to 
antibiotic penetration and metabolic changes such as 
slower growth rates [7, 12].
One current treatment used for salvaging biofilm-col-
onized catheters implicated in CLABSI is the application 
of antibiotic lock therapy (ALT). During ALT, supra-
therapeutic concentrations of antibiotic solutions are 
locked in the affected catheter for an extended amount 
of time [13, 14]. However, to our knowledge, the effect of 
ALT on S. marcescens biofilms has not yet been studied 
extensively in vivo nor in vitro. Another biofilm-control 
strategy centers on chemicals with no antimicrobial 
activity, which affects biofilm formation and adhesion by 
alteration of the bacterial microenvironment [12]. Recent 
reports have demonstrated the efficacy of polysorbate-80 
(PS80) a nonionic surfactant, in reducing the biofilm 
mass of Escherichia coli, Stenotrophomonas maltophilia, 
Listeria monocytogenes, and Pseudomonas fluorescens 
[15–17]. PS80 is a solubilizing and emulsifying agent 
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used in ointments, lotions, soaps as well as in medical 
preparations such as vitamin oils and anticancer agents 
[15]. In addition to PS80, ursolic acid (UA) is a plant-
derived agent shown to reduce Actinomyces viscosus, 
Streptococcus mutants, Vibrio harveyi, and Pseudomonas 
aeruginosa biofilm mass [18, 19]. Herein, we determined 
the effectiveness of high-dose antibiotic, PS80 and UA 




The tetracycline-resistant S. marcescens clinical isolate 
UT-383 was obtained from Dr. Jan Patterson (Division 
of Infectious Disease, Department of Medicine, The Uni-
versity of Texas Health Sciences Center at San Antonio) 
[2]. S. marcescens was grown on Luria–Bertani (LB) agar 
plates (LB-Lennox formulation) and incubated overnight 
at 37 °C. A single colony was transferred to LB broth and 
incubated overnight at 37 °C. The culture was then back 
diluted in fresh LB broth and incubated for 3 h at 37 °C 
to an optical density (OD621) of 0.5 nm. To establish the 
minimum inhibitory concentration (MIC) of ceftriaxone, 
kanamycin, gentamicin and chloramphenicol on S. marc-
escens. Planktonic grown bacteria were exposed to the 
latter antibiotics, plates were incubated overnight, and 
MIC was determined as the lowest concentration of anti-
biotics with no growth detected by spectrophotometry at 
OD621.
Biofilm growth and quantification
Biofilm growth was initiated by inoculating 4  ml of LB 
broth with 1 × 105 CFU of S. marcescens using a 6-well 
polystyrene plate (Corning Inc., Corning NY). Cultures 
were grown overnight at 37 °C. 3 ml of media were then 
gently aspirated and replaced with 1 ml of LB and 2 ml 
of Mueller–Hinton broth (MH) (control) or MH-based 
antibiotic solutions (ceftriaxone: 0.005, 0.05, 0.5  mg/ml; 
kanamycin: 0.625, 6.25, 62.5  mg/ml; gentamicin: 0.08, 
0.80, 8.0 mg/ml; and chloramphenicol: 0.08, 0.80 mg/ml). 
Solutions of PS80 were prepared to yield final concentra-
tions of 1, 0.1, and 0.01%, and UA to yield a final concen-
tration of 0.03 mg/ml. Biofilms were then returned to the 
incubator overnight. The media on each well was then 
aspirated and biofilms stained with 1% crystal violet for 
10  min, washed twice with 2  ml of 1×  PBS, dried, and 
photographed. A representative image of each biofilm 
was taken with a Leica LMD6 inverted microscope with 
a DFC3000G-1.3-megapixel monochrome camera (Leica 
Biosystems, Buffalo Grove, IL). Bacterial biofilms were 
then solubilized with 2  ml of 95% ethanol, rocked for 
30 min and the optical density at 540 nm of a 1:10 etha-
nol dilution was measured using an iMark Absorbance 
Microplate Reader (Bio-Rad Laboratories, Hercules, CA). 
Controls of each antibiotic were incubated sterile over-
night, stained, solubilized, and read in the same manner 
to account for background staining from each concentra-
tion of the solution.
Absorbance values were calculated by subtracting 
the background stain from each well. Values were then 
normalized to 1 by dividing by the mean growth of the 
bacteria-only controls of each experiment (which were 
calculated by subtracting the mean of all media-only 
wells from each bacteria-only control). A total of three 
experiments were carried out with ceftriaxone, kanamy-
cin, and gentamicin (5 total replicates), while four experi-
ments were carried out with chloramphenicol, PS80, and 
UA (7 total replicates).
Viability of biofilms treated with chloramphenicol or PS80
After 24  h of growth, biofilms were treated with chlo-
ramphenicol or PS80 and incubated for an extra 24  h 
at 37 °C. Biofilms were then washed gently with 2 ml of 
sterile PBS to dislodge remaining planktonic bacteria, 
and dried overnight at room temperature. Subsequently, 
1 ml of sterile PBS was added to each well and biofilms 
removed by scraping. The supernatant was serially 
diluted in PBS, then 100  µl of each dilution was plated 
on individual blood agar petri dishes and incubated 
overnight to quantify the viable colony-forming units in 
the biofilm [2, 20].
Antibiotics and other chemicals
Antibiotic solutions were made in Mueller–Hinton broth 
(MH). Ceftriaxone (Sigma-Aldrich, St. Louis MO), kana-
mycin (Sigma-Aldrich), gentamicin (Gibco, Grand Island 
NY), and chloramphenicol (Sigma-Aldrich). Polysorb-
ate-80 (Fisher Scientific, Fair Lawn NJ) and ursolic acid 
(Sigma-Aldrich).
Statistical analysis
Each set of experiments was then analyzed separately 
using Kruskal–Wallis ANOVA with multiple compari-
sons on GraphPad Prism version 7.0a (La Jolla CA).
Results
High concentrations of chloramphenicol reduce biofilm 
growth of S. marcescens
To test the susceptibility S. marcescens to multiple anti-
biotics, we co-cultured the latter in the presence of cef-
triaxone, kanamycin, gentamicin, chloramphenicol, 
tetracycline, and erythromycin. Planktonic S. marces-
cens demonstrated susceptibility to all tested antibiotics 
except tetracycline and erythromycin at various doses 
(Additional file 1: Table S1). We then tested the ability of 
the antibiotics mentioned above to reduce S. marcescens 
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biofilm biomass in  vitro. S. marcescens biofilms were 
treated with ceftriaxone, kanamycin, gentamicin, and 
chloramphenicol at 10, 100, and 1000 times the plank-
tonic minimum inhibitory concentration (MIC, see Addi-
tional file 2: Table S2). Biofilm biomass showed no change 
after treatment with 0.005, 0.05, 0.5 mg/ml of ceftriaxone 
(Fig.  1). At the lowest tested concentration of kanamy-
cin (0.625  mg/ml) biofilm biomass was reduced. How-
ever, at 62.5  mg/ml of kanamycin, no change in biofilm 
formation was observed. Similar results also occurred 
when gentamicin was used (Fig.  1). These findings sug-
gest a lack of dose-dependent effect in the reduction of 
S. marcescens biofilm biomass by kanamycin, gentamicin, 
and ceftriaxone; and raise the possibility that antibiotics 
promote biofilm formation.
Chloramphenicol is a last resort antibiotic used to treat 
infections such as tetracycline-resistant cholera [21] or 
brain abscesses caused by bacteria [22–24]. To deter-
mine if high doses of chloramphenicol could reduce 
biofilm biomass we co-cultured S. marcescens with 0.08 
and 0.80  mg/ml of the latter antibiotic. Biofilm mass as 
determined by crystal violet staining showed a significant 
decrease at both 0.08 mg/ml (P = 0.0003) and 0.80 mg/
ml (P < 0.0001) of chloramphenicol, with a greater reduc-
tion at 0.80  mg/ml indicating dose-dependence (Fig.  2). 
Finally, biofilms treated with either PS80 or UA had a 
minimal but not significant change in biomass (Fig.  2). 
Collectively, these results suggest that antibiotics com-
monly used for ALT are not sufficient to reduce biomass 
of biofilms formed by a clinical isolate of S. marcescens 
except for chloramphenicol.
PS80 1% and high dose chloramphenicol lessen the 
viability of S. marcescens biofilms
Quantification of viable bacteria from in  vitro biofilms 
treated with both PS80 and chloramphenicol showed a 
significant reduction in the number of colony-forming 
units recovered after treatment (Fig.  3). These results 
suggest that PS80 and chloramphenicol could not only 
decrease S. marcescens biofilm biomass but also its 
viability.
Discussion
The clinical guidelines from the Infectious Disease Soci-
ety of America recommends the use of ALT for catheter 
salvage [25]. Our study suggests that ALT is a viable strat-
egy against biofilms generated by a clinical isolate of S. 
marcescens depending on the selected antibiotics. The 
response to chloramphenicol and small doses of amino-
glycosides offer two possible avenues to treat S. marc-
escens contaminated catheters and reduce infections 
associated with this organism.
A major limitation of our study is that only one strain of 
S. marcescens was tested against our panel of antibiotics. 
To date, 8 out of 14 species of Serratia are documented 
to be related to human infections [1]. S. marcescens is 
known to be endogenously resistant to antibiotics such 
as colistin and cephalothin [26]. In the hospital setting 
Fig. 1 S. marcescens biofilms are partially resistant to ceftriaxone, gentamicin and kanamycin. a–c S. marcescens biofilms were treated with a 
ceftriaxone: 0.005, 0.05, 0.5 mg/ml; b kanamycin: 0.625, 6.25, 62.5 mg/ml; and c gentamicin: 0.08, 0.80, 8.0 mg/ml. Absorbance (540 nm) for antibi‑
otic experiments (mean + SD). Values are normalized to the mean control of each experiment. d Representative pictures of in vitro S. marcescens 
biofilms treated with ceftriaxone, kanamycin or gentamicin at shown concentrations. For multi‑group comparisons Dunn’s multiple‑comparison 
post‑test was used: *P < 0.05, **P ≤ 0.01, ***P ≤ 0.001
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bacteria from the Enterobacteriaceae family have demon-
strated to be extraordinary in their capability to acquire, 
transfer and express antimicrobial resistance [27]. For 
these reasons, another limitation of this report is that it 
might not represent all strains of S. marcescens as our 
clinical isolate might have gained other antimicrobial 
resistances in the healthcare setting not present in ref-
erence strains. Future studies are warranted to address 
these and other limitations. We are particularly inter-
ested in exploring the possibility that some antimicrobi-
als might be promoting biofilm formation.
Chloramphenicol effectivity against bacterial biofilms 
is still not well defined [23]. A recent report found no 
anti-biofilm activity of chloramphenicol against Staphy-
lococcus aureus, E. coli, and Micrococcus luteus. Impor-
tantly, the authors only used a concentration of only 
0.005 mg/ml, a concentration well below the planktonic 
MIC for our bacterium and only slightly higher than the 
MICs for their three isolates (maximum 0.0031 mg/ml) 
[28]. In contrast, our study shows that high doses (0.08 
and 0.80 mg/ml) of chloramphenicol reduce the mass of 
preformed S. marcescens biofilms, and the 0.80  mg/ml 
concentration decreases the viability of biofilms com-
pared with untreated controls. Together these results 
carry important implications for its potential in ALT. 
Importantly, since chloramphenicol is barely soluble 
in water, small amounts of methanol were added to 
facilitate solubility (yielding a final concentration of <5% 
methanol in the 0.80  mg/ml solution, and  <0.5% in the 
0.08  mg/ml solution); however, it seems unlikely that 
these small amounts of methanol influenced biofilm 
mass.
The use of chloramphenicol in systemic therapy has 
been limited by its toxicity, including fatal occurrences of 
granulocytopenia, aplastic anemia, and thrombocytope-
nia. The limitations mentioned above are avoided in ALT 
since the removal of the solution from the catheter mini-
mizes systemic exposure to antibiotics [28]. The broad 
spectrum of action, including against some multi-drug 
resistant bacteria, makes chloramphenicol an attractive 
candidate for treating CLABSI. Additionally, chloram-
phenicol is inexpensive and remains stable in the pres-
ence of heparin (which is commonly included in ALT 
to prevent catheter thrombosis). Further studies will be 
needed to examine the potential of chloramphenicol as a 
clinical treatment with other pathogens.
Conclusions
In our study, biofilms formed by a clinical isolate of S. 
marcescens were only killed by the use of chlorampheni-
col at ten and one hundred times concentrations used 
to kill planktonic bacteria, non-other of the antibiot-
ics tested had the same effect. These suggest that chlo-
ramphenicol might be utilized for ALT against not only 
Fig. 2 Chloramphenicol but polysorbate‑80 or ursolic acid reduces S. marcescens biofilm biomass. a–c S. marcescens biofilms were treated with 
a chloramphenicol: 0.08, 0.80 mg/ml, b ursolic acid at 0.03 mg/ml or c 1, 0.1 0.01% polysorbate‑80 (PS80). d Representative pictures of in vitro S. 
marcescens biofilms treated with chloramphenicol, polysorbate‑80 (PS80) and ursolic acid (UA) at shown concentrations. Absorbance (540 nm) for 
chemical experiments (mean + SD), values are normalized to the mean control of each experiment. For multi‑group comparisons Dunn’s multiple‑
comparison post‑test was used: *P < 0.05, **P ≤ 0.01, ***P ≤ 0.001
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S. marcescens but also other Gram-negative nosocomial 
pathogens.
Abbreviations
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